MD Anderson Research Highlights for June 29, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy...
MD Anderson and Turning Point Therapeutics announce strategic alliance to advance precision cancer therapies
The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development...
MD Anderson, Invectys and CTMC announce strategic collaboration for CAR T cell therapy development
The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...
MD Anderson Research Highlights for June 15, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include preclinical discoveries for combination therapies to treat breast, ovarian and colorectal cancers; a new treatment target for rare sarcomas; a novel CRISPR engineering approach to facilitate in vivo research;...
Androgen receptor signaling contributes to targeted therapy resistance in melanoma
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from...
Estimating tumor-specific total mRNA level predicts cancer outcomes
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA levels...
MD Anderson Research Highlights: EHA 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Genetic study offers new insights into DCIS biology, progression
A new study led by the global Cancer Grand Challenges PRECISION team, including researchers from The University of Texas MD Anderson Cancer...
MD Anderson researchers present encouraging results of early-stage clinical trials at 2022 ASCO Annual Meeting
CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising...
Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma
ABSTRACTS: 2006, 2511
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of...
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting
ABSTRACTS 7518, 7509, 8009
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being...
Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma
ABSTRACT: LBA11501
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses...
ASCO honors Eduardo Bruera, M.D., with Walther Cancer Foundation Supportive Oncology Award
Eduardo Bruera, M.D., chair of Palliative Care Medicine at The University of Texas MD Anderson Cancer Center, has received...
Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients
ABSTRACT LBA7502
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free...
MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer
The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the Cell Therapy...
MD Anderson Research Highlights for June 1, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...